Gilead’s lenacapavir under priority review could revolutionise HIV PrEP
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...
This New Drug Could Help End the HIV Epidemic—but US Funding Cuts Are Killing Its Rollout
Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...
Drug therapy lenacapavir may effectively control HIV in Uganda
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
GlobalData on MSN5d
Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP use
Lenacapavir is already approved under the name Sunlenca as an HIV treatment for patients resistant to other medication ...
News Medical on MSN4d
New HIV therapy lenacapavir shows high efficacy in Ugandan population
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
Science Daily3d
New therapy may effectively control HIV in Uganda
A multi-national, multi-institutional study investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.
Gilead Sciences, Inc. (GILD): Among Renaissance Technologies Portfolio’s Top Stock Picks
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
Managed Healthcare Executive4d
FDA Accepts NDA for Gilead's New HIV Prevention Shot
Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving ...
Bay Area Reporter4d
Twice-yearly PrEP could be available this summer
Twice-yearly lenacapavir PrEP could be available as early as this summer pending federal Food and Drug Administration ...
The Pharma Letter4d
Lenacapavir PDUFA date set for June
US biotech Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...
Monthly Prescribing Reference4d
Twice-Yearly Lenacapavir Gets Priority Review For HIV PrEP
The Food and Drug Administration (FDA) has accepted under Priority Review the New Drug Application (NDA) for lenacapavir, a long-acting HIV-1 capsid inhibitor, for the prevention of HIV as ...